On August 27, 2026 NovaBridge Biosciences (Nasdaq: NBP) ("NovaBridge" or the "Company"), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, reported that the Company’s leadership will participate in the following investor conferences in September 2026:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference details:

Cantor 2026 Global Healthcare Conference
Format: Fireside Chat and one-on-one meetings
Presenter: Srishti Gupta, MD, MPP, Chief Executive Officer, NovaBridge Biosciences
Date: Thursday, September 10, 2026
Time: 1:00 PM ET
Webcast Link: Here

H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside Chat and one-on-one meetings
Presenter: Srishti Gupta, MD, MPP, Chief Executive Officer, NovaBridge Biosciences
Date: Monday, September 14, 2026
Time: 9:30 AM ET
Webcast Link: Here

Webcasts of the Fireside chats will be accessible in the News & Events page of the NovaBridge website for 90 days.

(Press release, NovaBridge Biosciences, AUG 27, 2026, View Source [SID1234670402])

On August 27, 2026 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Varseta-M for the treatment of patients with relapsed/refractory metastatic colorectal cancer. Varseta-M is a potential first-in-class antibody drug conjugate directed toward epithelial cell adhesion molecule (EpCAM) with a topoisomerase-1 inhibitor payload.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Varseta-M was intentionally designed for patients with colorectal cancer based on the high expression of EpCAM in this cancer type. Receiving Fast Track Designation is an important milestone for the program and reflects its potential to address a highly unmet medical need in patients with relapsed/refractory metastatic colorectal cancer where we continue to work towards a planned first registrational trial in the first half of 2027," said Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics.

Fast Track Designation is intended to facilitate development and expedite the review of therapies for serious conditions with unmet medical needs.

(Press release, CytomX Therapeutics, AUG 27, 2026, View Source [SID1234670401])

On August 27, 2026 SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, reported the filing of a new Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). The DMF, filed under number 044612, covers exosomes derived from Gamma Delta T (GDT) cells. It was filed by JY BioMed Co., Ltd. ("JY BioMed"), the intellectual property holder of the GDT platform and SL Science’s licensor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This filing marks a significant milestone, as it extends the FDA-filed manufacturing and quality documentation across two formats of the same core technology: the GDT cells themselves, and the cell-free exosomes those cells secrete. A DMF streamlines future regulatory processes by providing the FDA with confidential chemistry, manufacturing, and controls (CMC) data that can be referenced in subsequent applications. Because CMC requirements are frequently a major bottleneck in cell therapy development, having this documentation already on file is expected to significantly reduce the groundwork required for downstream programs.

The cell-free exosome format also addresses a critical delivery challenge in oncology. Published preclinical research demonstrates that GDT-derived exosomes carry proteins capable of both directly triggering tumor cell death and stimulating the host’s own immune system. Furthermore, independent studies indicate these exosomes can work synergistically with radiotherapy and remain active in immunosuppressive tumor environments.

Crucially for SL Science’s focus on brain cancer, this format offers a potential solution to a well-known biological barrier. As the Company’s leadership recently highlighted in peer-reviewed literature, the primary constraint in treating glioblastoma is successfully delivering therapies across the blood-brain barrier. Unlike larger cells, extracellular vesicles such as exosomes have been shown in independent studies to actively cross an intact blood-brain barrier, reaching the central nervous system through a receptor-mediated biological route.

"What accumulates around a platform matters as much as the platform itself," said Mr. William Wang, Chairman and Chief Executive Officer of SL Science. "There is now manufacturing and quality documentation on file with the FDA for both the GDT cells and the exosomes those cells secrete – work no downstream program has to do again. And in brain cancer, where getting an effector to the tumor is the problem we ourselves have written about, a format that reaches the central nervous system by an active biological route is worth understanding properly."

(Press release, SL Science, AUG 27, 2026, View Source [SID1234670400])

On August 27, 2026 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, reported a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated endothelial cells. This dual-targeting approach is intended to address both tumor cells and tumor vasculature.

The trial is currently enrolling patients with unresectable, locally advanced or metastatic solid tumors. The collaboration will include longitudinal Signatera testing for circulating tumor DNA (ctDNA) to explore its value for treatment response monitoring during AGX101 treatment.

Natera’s Signatera test provides a personalized measure of ctDNA that may complement radiologic assessment. Longitudinal ctDNA assessments may provide additional information in patients treated with AGX101, particularly when imaging shows metabolic or structural changes whose relationship to viable tumor is uncertain.

"We believe AGX101 has the potential to offer a differentiated therapeutic approach for patients with advanced solid tumors," said Paul Jaminet, Ph.D., co-founder and CEO of Angiex. "This collaboration will allow us to evaluate whether longitudinal ctDNA measurements can complement imaging and improve our understanding of treatment response."

"Signatera provides additional depth into early biologic response assessment that can meaningfully advance our understanding of this novel drug class," said Eric Matthews, general manager, biopharma, at Natera. "We look forward to working with the Angiex team to generate molecular response data that can inform the development of AGX101 and advance this promising therapeutic approach."

(Press release, Natera, AUG 27, 2026, View Source [SID1234670399])

On August 27, 2026 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and RNA for sensitive downstream assays, supporting reliable detection across clinical molecular testing applications including liquid biopsy, oncology and infectious disease diagnostics.

"Clinical laboratories need automation solutions that combine proven extraction performance with the standardization, traceability and productivity needed for today’s molecular testing workflows," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. "The commercial launch of QIAsymphony Connect reflects our continued investment in automated sample preparation and strengthens our Sample to Insight portfolio by helping laboratories improve consistency and efficiency across clinical molecular testing."

QIAGEN has completed the FDA listing in the U.S. and the EUDAMED listing in Europe for QIAsymphony Connect, accomplishing significant regulatory milestones as the platform enters broader commercial availability.

Advancing routine clinical workflows

QIAsymphony Connect supports routine clinical molecular testing through following capabilities:

Standardized workflow automation: Integrated liquid handling, prefilled IVD reagent cartridges, automated load checks and guided workflow setup minimize run-to-run and operator-to-operator variability, enabling standardized walkaway workflows with less hands-on time while supporting reproducible nucleic acid extraction.
Complete sample traceability: Automated barcode reading of primary sample tubes and eluates, built-in audit trails and onboard process controls provide complete sample traceability and strengthen process safety throughout the extraction workflow.
High-throughput performance for sensitive molecular testing – in particular, liquid biopsy: Processing of up to 96 samples in four independent batches supports routine laboratory productivity. The novel bead collection and elution approach, together with sample input volumes ranging from a few microliters up to 10 mL, delivers highly concentrated DNA and RNA for sensitive downstream applications. This includes liquid biopsy, which analyzes tumor-derived material circulating in blood and requires sensitive detection of often low-abundance molecular targets, as well as other oncology and infectious disease applications.
Supporting existing and new customers

QIAsymphony Connect introduces enhanced usability, digital connectivity and workflow standardization while maintaining full backward compatibility with trusted QIAsymphony reagent kits and consumables. Their continued use across both platforms facilitates a smoother and faster migration to QIAsymphony Connect.

At the same time, laboratories implementing new molecular testing applications benefit from workflow enhancements designed to simplify routine operation and support standardized molecular testing.

QIAGEN has already received initial customer orders for QIAsymphony Connect, reflecting early market adoption as the platform enters broader commercial availability.

Early users have highlighted the platform’s intuitive guided workflow setup, comprehensive sample traceability and reduced hands-on time as important advantages for routine clinical testing. Users also cited the consistency of nucleic acid extraction and simplified run setup as key benefits across both established and newly implemented molecular testing workflows.

Learn more about QIAsymphony Connect at View Source

(Press release, Qiagen, AUG 27, 2026, View Source [SID1234670398])